NCT03610464View on ClinicalTrials.gov

Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years

PHASE4CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 7, 2018

Primary Completion Date

May 23, 2018

Study Completion Date

May 23, 2018

Conditions
Attention Deficit Hyperactivity Disorder
Interventions
DRUG

Amphetamine Extended Release Suspension [Dyanavel]

1 mL of study drug (AMPH EROS, 2.5 mg/mL), pharmacokinetic analysis

Trial Locations (1)

32751

Meridien Research, Inc., Maitland

All Listed Sponsors
lead

Tris Pharma, Inc.

INDUSTRY

NCT03610464 - Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years | Biotech Hunter | Biotech Hunter